← Leaderboards
Rolf A Brekken
The Hope Heart Institute
$6,600,768
Attributed
$9,584,136
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,584,136 · 10
By mechanism
R01$7,005,353 · 4
R21$1,166,939 · 3
T32$859,249 · 1
U54$470,451 · 1
F32$82,144 · 1
Top collaborators
- Thomas M Wilkie7 shared
- Kevin G Pinney4 shared
- Mary Lynn Trawick4 shared
- Jerry William Shay2 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTumorMalignant NeoplasmsSignal TransductionMalignant Neoplasm Of PancreasResponseTumor ProgressionMouse ModelNeoplasm MetastasisGrowthNeoplastic CellXenograft ProcedurePancreatic Ductal AdenocarcinomaStromal CellsCell ProliferationPathway InteractionsImmunePhenotypeChemotherapyCancer CellTumor MicroenvironmentPharmaceutical PreparationsBaseTumor-Immune System Interactions
Grant awards (31)
Translational Cancer Biology (TCB) T32 Training Program$426,923
T32 · FY2025 · CA · contact PI
Translational Cancer Biology (TCB) T32 Training Program$432,326
T32 · FY2024 · CA · contact PI
Inhibition of pleiotrophin to combat pancreatic cancer metastasis$421,685
R21 · FY2024 · CA · contact PI
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer$466,250
R01 · FY2023 · CA
Targeted inhibition in stromal TGFβ activity in pancreatic cancer$352,660
R01 · FY2023 · CA · contact PI
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer$466,250
R01 · FY2022 · CA
Targeted inhibition in stromal TGFβ activity in pancreatic cancer$352,660
R01 · FY2022 · CA · contact PI
Targeted inhibition in stromal TGFβ activity in pancreatic cancer$130,272
R01 · FY2022 · CA · contact PI
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer$475,608
R01 · FY2021 · CA
Targeted inhibition in stromal TGFβ activity in pancreatic cancer$359,711
R01 · FY2021 · CA · contact PI
Murimwa - Targeted inhibition in stromal TGFβ activity in pancreatic cancer$132,862
R01 · FY2021 · CA · contact PI
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer$490,013
R01 · FY2020 · CA
Targeted inhibition in stromal TGFβ activity in pancreatic cancer$374,691
R01 · FY2020 · CA · contact PI
Microenvironmental Transport for Immunotherapy in Pancreatic Cancer$233,282
U54 · FY2020 · CA · contact PI
Exploitation of RAS signaling to develop therapy and early detection strategies for PDA$420,093
R01 · FY2019 · CA · contact PI
Microenvironmental Transport for Immunotherapy in Pancreatic Cancer$237,169
U54 · FY2019 · CA · contact PI
Exploitation of RAS signaling to develop therapy and early detection strategies for PDA$454,817
R01 · FY2018 · CA · contact PI
Exploitation of RAS signaling to develop therapy and early detection strategies for PDA$454,817
R01 · FY2017 · CA · contact PI
Exploitation of RAS signaling to develop therapy and early detection strategies for PDA$435,921
R01 · FY2016 · CA · contact PI
Exploitation of RAS signaling to develop therapy and early detection strategies for PDA$440,978
R01 · FY2015 · CA · contact PI
Axl as a target for the therapy of pancreatic cancer$167,726
R21 · FY2014 · CA · contact PI
Axl as a target for the therapy of pancreatic cancer$207,495
R21 · FY2013 · CA · contact PI
GPCR regulation of progenitor cells in pancreatic cancer$162,538
R21 · FY2013 · CA · contact PI
GPCR regulation of progenitor cells in pancreatic cancer$207,495
R21 · FY2012 · CA · contact PI
Matricellular proteins as regulators of tumor progression$295,875
R01 · FY2010 · CA · contact PI
Matricellular proteins as regulators of tumor progression$295,875
R01 · FY2009 · CA · contact PI
Matricellular proteins as regulators of tumor progression$295,875
R01 · FY2008 · CA · contact PI
Matricellular proteins as regulators of tumor progression$310,125
R01 · FY2007 · CA · contact PI
SPARC AS A REGULATOR OF VEGF ACTIVITY$9,532
F32 · FY2002 · HL
SPARC AS A REGULATOR OF VEGF ACTIVITY$40,196
F32 · FY2001 · HL
SPARC AS A REGULATOR OF VEGF ACTIVITY$32,416
F32 · FY2000 · HL